

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-19. (Canceled)

20. (Currently Amended) A hydrophilic controlled release solid tablet formulation comprising a matrix comprising, as a substantially homogeneous admixture, about 5% to less than 80%, by weight of the tablet, of pregelatinized starch, an active ingredient that is 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof, and one or more viscous hydrophilic polymers, wherein said controlled release solid tablet formulation allows at least a two-fold reduction in dosing frequency, an increase in patient compliance, or an increase in therapeutic performance, as compared to a conventional dosage form.

21. (Previously Presented) The controlled release solid tablet formulation of claim 20, wherein said one or more hydrophilic polymers are selected from the group consisting of alkylcellulose, hydroxyalkylcellulose, hydroxyalkylalkylcellulose, carboxyalkylcellulose, alkali metal salts of carboxyalkylcellulose, natural, semi synthetic or synthetic polysaccharide, polyacrylic acid and salts thereof, polymethacrylic acid and the salts thereof, polyvinyl alcohol, polyvinylpyrrolidone, and polyalkylene oxides.

22. (Previously Presented) The controlled release solid tablet formulation of claim 20, wherein said one or more hydrophilic polymers are selected from the group consisting of hydroxypropyl cellulose and hydroxypropylmethylcellulose.

23. (Previously Presented) The controlled release solid tablet formulation of claim 22, wherein said hydroxypropylmethylcellulose has a viscosity in a range from about 3,500 mPa.s to about 100,000 mPa.s.

24. (Previously Presented) The controlled release solid tablet formulation of claim 22, wherein said hydroxypropylcellulose has a viscosity of less than about 1,500 mPa.s.

25. (Previously Presented) The controlled release solid tablet formulation of claim 20, wherein said one or more hydrophilic polymers are present in an amount from about 0.01 to about 80 % by weight.

26. (Previously Presented) The controlled release solid tablet formulation of claim 20, wherein at least two hydrophilic polymers are present in said formulation.

27. (Previously Presented) The controlled release solid tablet formulation of claim 26, wherein said at least two hydrophilic polymers are hydroxypropylcellulose and hydroxypropylmethylcellulose,

28. (Previously Presented) The controlled release solid tablet formulation of claim 27, wherein a ratio of said hydroxypropylcellulose to said hydroxypropylmethylcellulose ranges from 1:5 to 5:1.

29. (Canceled).

30. (Canceled).

31. (Canceled).

32. (Previously Presented) A method of providing controlled release of 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof, in a subject, comprising administering the controlled release solid tablet formulation of claim 20 to said subject.

33. (Currently Amended) A method of preparing a controlled release solid tablet formulation comprising mixing 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof with about 5% to less than 80%, by weight of the tablet, of pregelatinized starch and one or more hydrophilic polymers, to provide a substantially homogeneous admixture thereof, such that said controlled release solid tablet formulation allows at least a two-fold reduction in dosing frequency, an increase in patient compliance, or an increase in therapeutic performance, as compared to a conventional dosage form.

DOCKET NO.: JANS-0063(JAB1467USACNT)
Application No.: 10/674,701
Office Action Dated: May 28, 2008

**PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116**

34. (Canceled).

35. (Canceled).

36. (Currently Amended) The controlled release solid tablet formulation of claim 20 ~~[[30]]~~, wherein said pregelatinized starch is present at about 5% (w/w), by weight of the tablet.

37. (Previously Presented) The controlled release solid tablet formulation of claim 20, wherein said pregelatinized starch is present at about 5% to about 15%, by weight of the tablet.

38. (Canceled)

39. (Previously Presented) The controlled release solid tablet formulation according to any one of claims 20 to 28 or 36 to 37 wherein the tablet consists essentially of an optional coating and a controlled release matrix comprising a substantially homogeneous admixture comprising said active ingredient, said one or more viscous hydrophilic polymers, and said pregelatinized starch.